Compare MOLN & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MOLN | SRBK |
|---|---|---|
| Founded | 2004 | 1887 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.0M | 123.7M |
| IPO Year | 2021 | 2023 |
| Metric | MOLN | SRBK |
|---|---|---|
| Price | $4.33 | $17.85 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.38 | N/A |
| AVG Volume (30 Days) | 3.6K | ★ 25.9K |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.14% |
| EPS Growth | N/A | ★ 138.36 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $374.07 | N/A |
| P/E Ratio | ★ N/A | $87.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.36 | $11.93 |
| 52 Week High | $5.36 | $18.04 |
| Indicator | MOLN | SRBK |
|---|---|---|
| Relative Strength Index (RSI) | 50.44 | 68.44 |
| Support Level | $4.04 | $16.24 |
| Resistance Level | $4.51 | $18.04 |
| Average True Range (ATR) | 0.19 | 0.42 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 61.43 | 99.70 |
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.